BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9891508)

  • 1. Status of the p53, Rb and MDM2 genes in canine osteosarcoma.
    Mendoza S; Konishi T; Dernell WS; Withrow SJ; Miller CW
    Anticancer Res; 1998; 18(6A):4449-53. PubMed ID: 9891508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of the p53, Rb and MDM2 genes in osteosarcoma.
    Miller CW; Aslo A; Won A; Tan M; Lampkin B; Koeffler HP
    J Cancer Res Clin Oncol; 1996; 122(9):559-65. PubMed ID: 8781571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines.
    Levine RA; Fleischli MA
    Vet Pathol; 2000 Jan; 37(1):54-61. PubMed ID: 10643981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
    Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK
    Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas.
    Nasir L; Rutteman GR; Reid SW; Schulze C; Argyle DJ
    Cancer Lett; 2001 Dec; 174(1):83-9. PubMed ID: 11675155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas.
    Schneider-Stock R; Walter H; Radig K; Rys J; Bosse A; Kuhnen C; Hoang-Vu C; Roessner A
    J Cancer Res Clin Oncol; 1998; 124(10):532-40. PubMed ID: 9829856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation.
    Kanoe H; Nakayama T; Murakami H; Hosaka T; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Sasaki MS; Toguchida J
    Anticancer Res; 1998; 18(4A):2317-21. PubMed ID: 9703873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteosarcoma in blood relatives.
    Longhi A; Benassi MS; Molendini L; Macchiagodena M; Picci P; Bacci G
    Oncol Rep; 2001; 8(1):131-6. PubMed ID: 11115584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutation and absence of mdm2 amplification and Ki-ras mutation in 4-hydroxyamino quinoline 1-oxide induced transplantable osteosarcomas in rats.
    Kido A; Tsujiuchi T; Tsutsumi M; Takahama M; Okajima E; Kobitsu K; Miyauchi Y; Mii Y; Tamai S; Konishi Y
    Cancer Lett; 1997 Jan; 112(1):5-10. PubMed ID: 9029163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors.
    Yokoyama R; Schneider-Stock R; Radig K; Wex T; Roessner A
    Pathol Res Pract; 1998; 194(9):615-21. PubMed ID: 9793960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog.
    Johnson AS; Couto CG; Weghorst CM
    Carcinogenesis; 1998 Jan; 19(1):213-7. PubMed ID: 9472714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53 gene mutations in osteosarcomas in the dog.
    van Leeuwen IS; Cornelisse CJ; Misdorp W; Goedegebuure SA; Kirpensteijn J; Rutteman GR
    Cancer Lett; 1997 Jan; 111(1-2):173-8. PubMed ID: 9022143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.
    Lonardo F; Ueda T; Huvos AG; Healey J; Ladanyi M
    Cancer; 1997 Apr; 79(8):1541-7. PubMed ID: 9118036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 gene mutations in canine osteosarcoma.
    Kirpensteijn J; Kik M; Teske E; Rutteman GR
    Vet Surg; 2008 Jul; 37(5):454-60. PubMed ID: 18986312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
    Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
    Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alterations of MDM2 and p53 genes in bone tumors].
    Zhou X; Gao L; Zhe X
    Zhonghua Bing Li Xue Za Zhi; 1997 Oct; 26(5):270-2. PubMed ID: 10374333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
    Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection of p53 and MDM2 gene expression in osteosarcoma with biotin-labelled in situ].
    Wang X; Wang S; Feng C
    Zhonghua Wai Ke Za Zhi; 1997 Mar; 35(3):178-80. PubMed ID: 10374529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
    Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
    Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.